Retatrutide vs Tirzepatide: What the Research Compares

The short version: similar class, different receptor count

Retatrutide vs tirzepatide is a comparison that comes up constantly in research communities, and it is worth framing carefully before the numbers. Tirzepatide is an FDA-approved dual agonist — it activates two hormone receptors (GIP and GLP-1). Retatrutide is an investigational triple agonist — it activates those same two plus the glucagon receptor. Both are made by Eli Lilly. The extra glucagon arm in retatrutide appears to add energy expenditure on top of the appetite-suppression and insulin-enhancement effects shared with tirzepatide. In the Phase 2 data available today, retatrutide produced a larger mean weight reduction than tirzepatide's Phase 3 figures — but these come from different trials in different populations at different stages of development. Retatrutide is not approved; tirzepatide is. A direct head-to-head trial is underway within the TRIUMPH program, but results are not yet available. This page compares what the published record says.

Mechanism: dual vs triple agonism

Both compounds act on GIP and GLP-1 receptors via class-B GPCR signaling, producing glucose-dependent insulin augmentation and appetite suppression. The critical difference is the glucagon receptor arm in retatrutide:

• Tirzepatide: GIP + GLP-1 dual agonist (FDA-approved). No GCGR activity.
• Retatrutide: GIP + GLP-1 + glucagon triple agonist (investigational). GCGR activation adds thermogenic energy expenditure and hepatic lipid mobilization ^[3][6].

Cryo-EM structures of retatrutide confirm simultaneous triple receptor engagement ^[3]. The relative GCGR potency of retatrutide is 0.3× endogenous glucagon — partial activation tuned to increase energy expenditure without causing hyperglycemia ^[3].

A 2025 review in Current Atherosclerosis Reports identifies the glucagon-driven thermogenic contribution as the principal mechanism for the incremental weight loss above dual agonism ^[11]. A 2025 multi-incretin review in Peptides frames both agents as part of a rapidly expanding incretin-analog class with emerging benefit across metabolic comorbidities ^[12].

Efficacy figures: Phase 2 retatrutide vs Phase 3 tirzepatide

The following comparison uses published trial figures. Cross-trial comparisons have known limitations: different populations, enrollment criteria, trial durations, endpoint definitions, and development stages all affect results. These figures are the best currently available published data.

Body-weight reduction (mean %):

| Compound | Dose | Trial type | Duration | Mean weight change | |----------|------|-----------|---------|-------------------| | Retatrutide | 12 mg/wk | Phase 2 (obesity) ^[1] | 48 wk | −24.2% | | Retatrutide | 8 mg/wk | Phase 2 (obesity) ^[1] | 48 wk | −22.8% | | Tirzepatide | 15 mg/wk | Phase 3 (obesity) | 72 wk | ~−22.5% | | Retatrutide (T2D) | 12 mg/wk | Phase 2 (T2D) ^[2] | 36 wk | −16.94% |

Note: Tirzepatide Phase 3 obesity figure is from its SURMOUNT-1 trial — a different trial design, longer duration, larger enrollment. Comparing Phase 2 and Phase 3 figures is methodologically imperfect.

HbA1c reduction in type 2 diabetes:

• Retatrutide 12 mg (Phase 2): −2.02% vs −0.01% placebo at 24 weeks ^[2].
• Tirzepatide's Phase 3 T2D trials (SURPASS series) reported HbA1c reductions of −1.87% to −2.09% at the highest dose levels across 40 weeks.

Liver fat (MASLD):

• Retatrutide 12 mg (Phase 2a): −82.4% relative liver-fat reduction at 24 weeks ^[5].
• Tirzepatide: liver-fat Phase 3 data (SYNERGY-NASH trial) are still emerging; Phase 2 data suggested significant reductions, less quantitatively characterized in published form as of mid-2026.

Safety comparison

Both compounds share GI adverse events (nausea, vomiting, diarrhea) as the primary tolerability challenge. Key differences in the published record:

• Heart-rate increase: Retatrutide produced a dose-dependent mean increase of approximately 5–7 bpm peaking around week 24 ^[1]. Tirzepatide's Phase 3 data show a smaller heart-rate signal at approved doses.
• GI discontinuation: Retatrutide had an 18% discontinuation rate at 12 mg from GI events ^[1]. Tirzepatide's Phase 3 data showed discontinuation rates broadly similar to retatrutide's Phase 2 figures at the highest dose.
• Lean-mass reduction: Reported for both compounds; a 2025 Lancet Diabetes & Endocrinology substudy confirmed absolute lean-mass reduction alongside fat loss for retatrutide ^[4].
• Long-term outcomes: Tirzepatide has completed Phase 3 trials for T2D and obesity and carries approved labeling with cardiovascular outcomes data in development. Retatrutide's long-term outcomes trials are ongoing ^[9][10].

Head-to-head safety comparison is not possible from published data alone — neither compound has been studied in the same trial against the other.

The head-to-head trial: TRIUMPH active-comparator arm

Eli Lilly's TRIUMPH Phase 3 program includes an active-comparator arm comparing retatrutide directly against tirzepatide. Results from this trial are not available as of mid-2026. It is the only source that can establish a direct, controlled efficacy and safety comparison between the two compounds in the same population under the same protocol.

Until those data are published, retatrutide results represent the best available one-sided picture: what retatrutide has measured in its own trials, which is substantial.

Approval and access status

Tirzepatide: FDA-approved for type 2 diabetes (2022) and obesity (2023). Available by prescription through licensed healthcare providers.

Retatrutide: Investigational. Not approved by any regulator. Not available by prescription. In active Phase 3 trials ^[7][9][10]. No NDA submitted as of mid-2026.

This distinction matters for any practical comparison: tirzepatide is a drug with an established regulatory track record, real-world pharmacovigilance data, and an approved dosing schedule. Retatrutide's full safety profile remains to be established through Phase 3 completion and regulatory review.